Loading…
science
Hosted by Eswar Krishnan, MD · science · EN · 11 episodes
Welcome to our podcast, designed specifically for biotech executives passionate about drug development. Join us as we explore a wide range of engaging topics, from cutting-edge advancements in translational sciences to the latest regulatory updates. Let’s navigate this dynamic landscape together and stay ahead of the curve! www.drugdevelop.com
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Public web form
Booking probability
25%
Guest openness
Selective
Sign up to generate a grounded pitch for Drug Development Executive.
Signup to Generate a PitchDrug Development Executive is a science podcast hosted by Eswar Krishnan, MD, with 11 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.
Eswar Krishnan, MD hosts Drug Development Executive, a science show with 11 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Drug Development Executive
<p>This podcast summarizes the therapeutic landscape and the underlying molecular understanding of the causal pathways in lupus.</p> <br/><br/>This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe
Drug Development Executive
<p>CAR-T Illustration. Courtesy New Scientist</p><p></p><p>A recent head-to-head study assessed the comparative effectiveness of different B-cell depletion strategies in patients with autoimmune diseases, specifically comparing protein-based therapies like obinutuzumab (OBI), blinatumomab (BLI), and rituximab (RTX) with cell-based CD19 chimeric antigen receptor (CAR) T-cell therapy. Researchers analyzed lymph node biopsies to assess the extent of B-cell depletion and changes in follicular architecture. They documented that CAR-T was most effective in depleting B cells and disrupting follicular architecture, and concluded that these data indicate potential superiority of CAR-T cell therapies.</p><p></p><p></p> <br/><br/>...
Drug Development Executive
<p></p> <br/><br/>This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe
Drug Development Executive
<p>New B cell depleters in development may offer superior impact on the immune system, durably "reset" the immune system, potentially cure conditions like pre-Type 1 Diabetes and SLE, or allow celiac disease patients to tolerate gluten again. </p> <br/><br/>This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe
Drug Development Executive
<p>This podcast discusses the role of inflammation, specifically interleukin-6 (IL-6) signaling, in cardiovascular diseases (CVD), including atherosclerosis and myocardial infarction (MI). We discuss the therapeutic potential of blocking IL-6 or its receptor (IL-6R) with drugs like tocilizumab and ziltivekimab, highlighting their ability to reduce inflammatory markers, such as C-reactive protein (CRP), and potentially improve patient outcomes in conditions like ST-elevation myocardial infarction (STEMI) and rheumatoid arthritis (RA). The "ZEUS trial" is presented as a significant ongoing study evaluating ziltivekimab's impact on major adverse cardiovascular events in high-risk patients. The podcast balances the potential benefits of these treatments with...
Sponsor detection runs nightly. Check back soon.
Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
FAQs
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
